<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Predictors of survival in heart failure with reduced ejection fraction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Predictors of survival in heart failure with reduced ejection fraction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Predictors of survival in heart failure with reduced ejection fraction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Heart failure (HF) is a common clinical syndrome associated with a mortality rate that varies with the severity of disease. Among patients with HF who are considering therapies such as heart transplantation, left ventricular (LV) assist device placement, or palliative care, prognostic information can further inform a discussion of the risks and benefits of therapy. However, for most diagnostic and treatment decisions, the role of prognosis is limited.</p><p>The following discussion will review the major clinical and laboratory predictors of survival in patients with HF due to systolic dysfunction.</p><p>The overall prognosis of HF and the predictors in patients with diastolic dysfunction are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3501.html" rel="external">"Prognosis of heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MAJOR PREDICTORS OF SURVIVAL</span><span class="headingEndMark"> — </span>A major challenge in the management of HF is the accurate identification of those patients who have a poor prognosis and who would therefore be most likely to benefit from intensive medical therapy and/or cardiac transplantation. Many univariate predictors of reduced survival have been identified in HF  (<a class="graphic graphic_table graphicRef75049" href="/z/d/graphic/75049.html" rel="external">table 1</a>). Identification of these factors should be part of the initial evaluation of any patient with HF. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p>The most frequently used factors for predicting survival in patients with systolic HF, many of which are direct or indirect measures of the severity of cardiac dysfunction, include:</p><p class="bulletIndent1"><span class="glyph">●</span>High New York Heart Association (NYHA) functional class  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severity of the reductions in LV ejection fraction (LVEF) and reduced cardiac index (CI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant diastolic dysfunction, as established by a mitral flow velocity pattern on Doppler echocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced right ventricular function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low peak VO<sub>2</sub> with maximal exercise and exercise hemodynamics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Markers of reduced tissue perfusion including low mean arterial pressure, decreased arterial pulse pressure, renal insufficiency (creatinine clearance &lt;60 mL/min), and an attenuated response to diuretics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated plasma levels of natriuretic hormones B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP). (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure", section on 'Prognosis'</a>.)</p><p></p><p>A lack of hemodynamic improvement with therapy, as indicated by failure to reduce LV filling pressure and persistence of signs of congestion (orthopnea, jugular venous distension, edema, weight gain, or increased need for diuretics), is also associated with a poorer prognosis [<a href="#rid1">1</a>].</p><p>In addition to these cardiac parameters, comorbid factors and the cause of the HF are important determinants of prognosis. As examples, the prognosis is worse in patients with diabetes mellitus [<a href="#rid2">2,3</a>] and ischemic cardiomyopathy in which the extent of the coronary artery disease is important [<a href="#rid4">4,5</a>]. Ventricular tachycardia is also an adverse prognostic factor [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H3"><span class="h2">NYHA functional class</span><span class="headingEndMark"> — </span>The NYHA criteria are most often used to assess the functional class of patients with HF  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Class I – No limitation during ordinary activity</p><p class="bulletIndent1"><span class="glyph">●</span>Class II – Slight limitation by shortness of breath and/or fatigue during moderate exertion or stress</p><p class="bulletIndent1"><span class="glyph">●</span>Class III – Symptoms with minimal exertion that interfere with normal daily activity</p><p class="bulletIndent1"><span class="glyph">●</span>Class IV – Inability to carry out any physical activity</p><p></p><p>Prospective studies evaluating the use of ACE inhibitors have demonstrated a strong relationship between the functional class and mortality  (<a class="graphic graphic_figure graphicRef63748" href="/z/d/graphic/63748.html" rel="external">figure 1</a>) [<a href="#rid6">6,8-10</a>].</p><p>These findings in control groups <strong>not</strong> receiving an ACE inhibitor can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic patients (class I) have a one- and four-<strong>year</strong> mortality rate of 5 and 19 percent  (<a class="graphic graphic_figure graphicRef75136" href="/z/d/graphic/75136.html" rel="external">figure 2</a>) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with NYHA class II or III HF have a one- and four-<strong>year</strong> mortality rate of 15 and 40 percent  (<a class="graphic graphic_figure graphicRef70015" href="/z/d/graphic/70015.html" rel="external">figure 3</a>) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with NYHA class IV do much worse with 6- and 12-<strong>month</strong> mortality rates of 44 and 64 percent in one large trial  (<a class="graphic graphic_figure graphicRef62325" href="/z/d/graphic/62325.html" rel="external">figure 4</a>) [<a href="#rid10">10</a>].</p><p></p><p>These observations indicate the importance of early treatment of HF in an attempt to slow progression to more severe disease. As an example, the improved outcome in patients treated with an ACE inhibitor is due primarily to better preservation of myocardial function. </p><p class="headingAnchor" id="H4"><span class="h2">Left ventricular ejection fraction</span><span class="headingEndMark"> — </span>Dilated cardiomyopathy is characterized by a variable reduction in LVEF, the assessment of which is probably the most frequently performed cardiac function test in patients with HF. Clinically evident HF due to systolic dysfunction is generally not apparent until the LVEF falls below 35 to 40 percent, as determined by echocardiography or contrast or radionuclide angiography. (See  <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a>.)</p><p>There is, however, no predictable relationship between symptoms or exercise tolerance and the LVEF. Some patients are asymptomatic with an LVEF below 20 percent, while others are moribund with an LVEF above 30 percent.</p><p>In general, survival is shorter in patients with lower LVEFs  (<a class="graphic graphic_figure graphicRef54758" href="/z/d/graphic/54758.html" rel="external">figure 5</a> and <a class="graphic graphic_figure graphicRef82195" href="/z/d/graphic/82195.html" rel="external">figure 6</a>) [<a href="#rid11">11-14</a>]. As an example, the relationship between LVEF and outcome was evaluated in 5010 patients enrolled in the Val-HeFT trial in whom echocardiograms were obtained at baseline [<a href="#rid11">11</a>]. Decreasing quartiles of LVEF were associated with increasing all-cause mortality at 23 months. Patients in the first quartile (mean LVEF 35 percent) had a significantly lower mortality rate than those in the fourth quartile (mean LVEF 17 percent) (14 versus 26 percent mortality, risk ratio 0.5). An LVEF below 20 percent is typically associated with poor survival [<a href="#rid15">15,16</a>]; some recommend cardiac transplantation in all such patients who are eligible [<a href="#rid15">15</a>].</p><p>However, relying on only a univariate predictor such as the LVEF to estimate survival is not very sensitive in the individual patient. As mentioned above, large trials have demonstrated that patients with NYHA class II or III HF have a worse prognosis than those who are asymptomatic. Despite the difference in outcome, the difference in mean LVEF between asymptomatic and symptomatic patients in these trials was small: 28 to 31 percent in asymptomatic patients [<a href="#rid8">8,17</a>] versus 25 percent in patients with moderate symptoms [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Concomitant diastolic dysfunction</span><span class="headingEndMark"> — </span>Concomitant diastolic dysfunction is associated with decreased survival among patients with HF and a reduced LVEF. Studies evaluating diastolic compliance with Doppler echocardiography have shown that altered transmitral flow (short deceleration time ≤115 ms, and an early-to-late flow velocity or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F195749&amp;token=c1zrDbt3FKY9s3hnnz3WHo%2FquURAJO5IGaTkA3b%2BDySoFVCzB%2Fo4sL35bz%2F120m5yvztpZE60NrYkkSFQR8rKw%3D%3D&amp;TOPIC_ID=3477" target="_blank">E/A ratio</a> &gt;1  (<a class="graphic graphic_figure graphicRef72146" href="/z/d/graphic/72146.html" rel="external">figure 7</a>)) is a powerful independent predictor of mortality or the need for transplantation among patients with HF  (<a class="graphic graphic_figure graphicRef55685" href="/z/d/graphic/55685.html" rel="external">figure 8</a>) [<a href="#rid18">18-22</a>]. (See  <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a>.)</p><p>The prognostic value of abnormal mitral flow velocity may be enhanced by assessing changes in this parameter during alterations in loading conditions  (<a class="graphic graphic_figure graphicRef72146" href="/z/d/graphic/72146.html" rel="external">figure 7</a>). This was illustrated in a report of 173 patients with chronic HF (53 percent ischemic cardiomyopathy) that measured the outcomes at 17 months in four subgroups that were distinguished by differences in changes in mitral valve flow velocity observed during <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> infusion (resulting in a reversible or nonreversible restrictive pattern) and passive leg lifting (resulting in a stable or nonstable nonrestrictive pattern) [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An irreversible restrictive pattern was associated with a 51 percent cardiac event rate (cardiac death or urgent transplantation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An unstable nonrestrictive pattern was associated with a 33 percent cardiac event rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A reversible restrictive pattern was associated with a 19 percent cardiac event rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A stable nonrestrictive pattern was associated with a 6 percent cardiac event rate.</p><p></p><p>Support for these observations comes from a study of 144 patients with HF (76 percent ischemic cardiomyopathy) who initially had a restrictive pattern on Doppler echocardiography; this test was repeated after six months of optimal medical therapy that included <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, diuretics, an ACE inhibitor, and a beta blocker [<a href="#rid21">21</a>]. At a mean follow-up of 26 months, patients with reversal of the restrictive pattern at six months had a lower cardiac mortality (11 versus 37 percent) and a lesser likelihood of being admitted to the hospital for worsening of HF (11 versus 54 percent) than those with persistence of the restrictive pattern.</p><p>The effect of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress on a restrictive pattern also appears to have prognostic value. This was illustrated in a review of 69 patients with ischemic dilated cardiomyopathy: 42 had a restrictive LV filling at rest, which reverted to a nonrestrictive pattern in 24 [<a href="#rid23">23</a>]. The patients with a persistent restrictive pattern had a significantly lower rate of survival at three years compared with those with a reversible restrictive pattern or those with a nonrestrictive pattern at rest (49 versus 79 and 89 percent, respectively). Persistence of the restrictive pattern was associated with a marked rise in left atrial pressure and a markedly attenuated inotropic response.</p><p>The presence of a restrictive pattern on Doppler echocardiogram also adds incremental predictive value to peak VO<sub>2</sub>, a measure of functional capacity, for establishing the prognosis in patients with HF [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3503.html" rel="external">"Exercise capacity and VO2 in heart failure"</a>.)</p><p>Other indicators of elevated LV filling pressure due to diastolic dysfunction and a restrictive pattern include a high pulmonary capillary wedge pressure (PCWP) and increased lung uptake of thallium (high thallium lung/heart ratio) on stress imaging. The latter finding may have incremental prognostic value over clinical and other imaging findings [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Right ventricular function</span><span class="headingEndMark"> — </span>Right ventricular systolic dysfunction also may contribute to prognosis in patients with HF [<a href="#rid26">26-30</a>]. Echocardiographic measurements of reduced right ventricular function include a reduction in right ventricular ejection fraction (RVEF), right ventricular enlargement, and tricuspid regurgitation. (See  <a class="medical medical_review" href="/z/d/html/5330.html" rel="external">"Echocardiographic recognition of cardiomyopathies"</a>.)</p><p>The prognostic importance of right ventricular function was illustrated in a series of 205 patients with class II or III HF; the RVEF was an independent predictor of one- and two-year survival and event-free cardiac survival [<a href="#rid29">29</a>]. At two years, the event-free survival rates from cardiovascular mortality and urgent transplantation for those with an RVEF ≥35 percent, ≥25 to &lt;35 percent, and &lt;25 percent were 93, 77, and 59 percent, respectively  (<a class="graphic graphic_figure graphicRef54666" href="/z/d/graphic/54666.html" rel="external">figure 9</a>). A similar adverse effect on outcome is seen with right ventricular enlargement, which is often associated with more severe tricuspid regurgitation  (<a class="graphic graphic_figure graphicRef52318" href="/z/d/graphic/52318.html" rel="external">figure 10</a>) [<a href="#rid27">27</a>], an abnormality that itself is associated with a worse prognosis  (<a class="graphic graphic_figure graphicRef51483" href="/z/d/graphic/51483.html" rel="external">figure 11</a>) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Pulmonary artery pressure</span><span class="headingEndMark"> — </span>Impaired right ventricular contractility in patients with left-sided HF may be due to primary myocardial disease or to poor LV function with an elevated pulmonary artery pressure. Right ventricular dysfunction appears to be of prognostic importance only when associated with elevated pulmonary artery pressure; assessment of right ventricular function in patients with normal pulmonary artery pressure does not improve risk stratification  (<a class="graphic graphic_figure graphicRef56623" href="/z/d/graphic/56623.html" rel="external">figure 12</a>) [<a href="#rid30">30</a>].</p><p>The importance of an elevated pulmonary artery pressure was further addressed in a prospective study of 1134 patients with a new cardiomyopathy who underwent right heart catheterization and endomyocardial biopsy and were followed for 4.4 years [<a href="#rid32">32</a>]. With a multivariate model, mean pulmonary artery pressure was the most important hemodynamic predictor of death, especially in the 93 patients (8.3 percent) with a diagnosis of myocarditis. For each 5 mmHg increase in baseline mean pulmonary artery pressure, the mortality in those with and without myocarditis increased with a relative hazard of 1.85 and 1.23, respectively.</p><p class="headingAnchor" id="H9"><span class="h2">Other echocardiographic findings</span><span class="headingEndMark"> — </span>In addition to the LVEF and diastolic and right ventricular function, a number of other echocardiographic findings have been associated with prognosis. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>LV dilatation or an LV end-diastolic volume index &gt;120 mL/m<sup>2</sup> [<a href="#rid11">11,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A restrictive mitral filling pattern and an LV systolic diameter index &gt;2.75 cm/m<sup>2</sup>, particularly if associated with a QRS duration &gt;144 ms [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased LV mass ≥298 g [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased left atrial size (dimension ≥4.17 or volume index &gt;68.5 mL/m<sup>2</sup> or 63 mL/m<sup>2</sup>)  (<a class="graphic graphic_figure graphicRef77947" href="/z/d/graphic/77947.html" rel="external">figure 13</a>) [<a href="#rid12">12,35,36</a>].</p><p></p><p>Augmentation of LVEF during <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography is also of prognostic importance in patients with an idiopathic dilated cardiomyopathy [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/1528.html" rel="external">"Dobutamine stress echocardiography in the evaluation of hibernating myocardium"</a>.)</p><p class="headingAnchor" id="H9378047"><span class="h2">QRS prolongation and LBBB</span><span class="headingEndMark"> — </span>Among patients with HF, a QRS duration ≥120 ms is common and is associated with a significant increase in mortality. As an example, in a retrospective analysis from the EVEREST trial, 45 percent of 2962 enrolled patients hospitalized for HF had a QRS duration ≥120 ms [<a href="#rid39">39</a>]. QRS prolongation was associated with increased all-cause mortality (adjusted hazard ratio [HR] 1.28, 95% CI 1.10-1.49) at a median of 9.9 months follow-up.</p><p>The worse outcomes with QRS prolongation have been attributed in part to ventricular dyssynchrony resulting from the conduction defect. Many such patients are treated with cardiac resynchronization (biventricular pacing), since randomized trials have shown a clear survival benefit. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p>Left bundle branch block (LBBB) on electrocardiogram (ECG), which is seen in 25 percent of patients with HF, is associated with increased all-cause [<a href="#rid40">40,41</a>] and sudden death mortality [<a href="#rid40">40</a>]. In analyses including LVEF, LBBB was an independent risk predictor of mortality in some studies [<a href="#rid40">40</a>] but not others [<a href="#rid41">41</a>], suggesting that LBBB may be a marker for but not a direct cause of increased mortality risk. (See  <a class="medical medical_review" href="/z/d/html/914.html" rel="external">"Left bundle branch block"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Exercise variables</span><span class="headingEndMark"> — </span>Because exercise requires an increase in cardiac work, evaluation of exercise capacity and cardiac function during exercise are effective ways of demonstrating a limitation in maximal cardiac performance, and thus, the severity of HF. Exercise may also reveal limitation in function that is not evident by history. Several exercise parameters including peak VO<sub>2</sub>, six-minute walk distance, and exercise hemodynamics have been correlated with patient survival. The predictive value of exercise parameters is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3503.html" rel="external">"Exercise capacity and VO2 in heart failure"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Neurohumoral activation and heart rate</span><span class="headingEndMark"> — </span>The low output state in HF results in multiple physiologic responses due to increased release of neurohormones. These include hyponatremia and elevated plasma concentrations of norepinephrine, BNP, renin, endothelin-1, and big endothelin-1  (<a class="graphic graphic_figure graphicRef58128 graphicRef55554 graphicRef59265 graphicRef78693 graphicRef58488" href="/z/d/graphic/58128.html" rel="external">figure 14A-E</a>) [<a href="#rid42">42-48</a>]. (See  <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Neurohumoral adaptations'</a>.)</p><p>At present, only the plasma sodium and BNP concentrations are measured clinically:</p><p class="bulletIndent1"><span class="glyph">●</span>Otherwise-unexplained hyponatremia is a poor prognostic finding. In a study of patients with severe HF, for example, patients with a plasma sodium concentration less than 137 meq/L had more than a 50 percent reduction in median survival (164 versus 373 days)  (<a class="graphic graphic_figure graphicRef55554" href="/z/d/graphic/55554.html" rel="external">figure 14B</a>) [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/2321.html" rel="external">"Hyponatremia in patients with heart failure", section on 'Predictor of adverse prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevations in plasma BNP predict reduced survival in patients with chronic and acute decompensated HF  (<a class="graphic graphic_figure graphicRef78693" href="/z/d/graphic/78693.html" rel="external">figure 14D</a>) [<a href="#rid44">44-46,49-53</a>]. They also predict an increased risk for sudden death [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure", section on 'Prognosis of HF'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An elevated heart rate, generally reflecting activation of the sympathetic nervous system, is also associated with a worse outcome [<a href="#rid55">55-57</a>] (see  <a class="medical medical_review" href="/z/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management"</a>). In an analysis of the placebo group in the BEAUTIFUL trial, cardiovascular outcomes were compared in 2693 patients with heart rates of ≥70 bpm and 2745 patients with heart rates &lt;70 bpm [<a href="#rid57">57</a>]. All patients had coronary artery disease, LVEF &lt;40 percent, and a resting heart rate of ≥60 bpm. For every 5 bpm increase, there were significant increases in cardiovascular death (8 percent), admission to hospital for HF (16 percent), and coronary revascularization (8 percent). This sign, though useful, is often absent in patients who are receiving adequate doses of a beta blocker.</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Signs of reduced tissue perfusion</span><span class="headingEndMark"> — </span>Clinical signs of reduced tissue perfusion are indicative of more severe disease and a worse prognosis. These include a low mean arterial blood pressure, renal insufficiency, an attenuated response to diuretics, and lack of hemodynamic improvement with therapy, as indicated by failure to reduce LV filling pressure, which are all also associated with a poorer prognosis [<a href="#rid58">58-63</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Low blood pressure</span><span class="headingEndMark"> — </span>Low systolic, diastolic, and mean arterial blood pressures have all been associated with increased mortality in patients with HF [<a href="#rid58">58,64</a>]. The mean arterial blood pressure can be estimated from the following formula:</p><div class="formulaContainer"><div class="formula"><p>Mean arterial pressure  =  (systolic blood pressure  +  [2  x  diastolic blood pressure]  /  3)</p></div></div><p>In the SOLVD trial, each 10 mmHg decrease in baseline mean arterial pressure was associated with a 14 percent increase in total and cardiovascular mortality [<a href="#rid58">58</a>], while a post-hoc analysis from the DIG study database found that mortality was highest in patients with systolic blood pressure &lt;100 mmHg and diastolic blood pressure &lt;60 mmHg [<a href="#rid64">64</a>].</p><p>A narrowing of the pulse pressure is also indicative of a decrease in cardiac output.</p><p class="headingAnchor" id="H18"><span class="h2">Reduced glomerular filtration rate</span><span class="headingEndMark"> — </span>There are a number of important interactions between heart disease and kidney disease. The interaction is bidirectional as heart disease can affect renal function and renal disease can affect cardiac function. As an example, reduced renal function is associated with increased mortality in patients with HF, as will be discussed below. On the other hand, patients with chronic kidney disease have an increased risk of both atherosclerotic cardiovascular disease and HF, and cardiovascular disease is responsible for up to 50 percent of deaths in patients with renal failure. In addition, acute or chronic dysfunction of the heart or kidneys can induce acute or chronic dysfunction in the other organ. The term cardiorenal syndrome has been applied to these interactions. (See  <a class="medical medical_review" href="/z/d/html/13606.html" rel="external">"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology"</a>.)</p><p>A reduced glomerular filtration rate (GFR) is associated with increased mortality risk in patients with HF. The magnitude of the effect can be illustrated by the findings in a systematic review of 16 studies with over 80,000 patients [<a href="#rid65">65</a>]. The mortality rate at a follow-up of one year or more was 24 percent in those with a normal GFR compared with 38 and 51 percent in patients with mild and moderate to severe reductions in GFR, respectively (adjusted HR 1.6 and 2.3). An elevated blood urea nitrogen (blood urea) is also associated with increased mortality, an effect that may be in part independent of the GFR. Optimal management of these patients is not well defined. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15619.html" rel="external">"Cardiorenal syndrome: Prognosis and treatment", section on 'Reduced GFR and prognosis'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Reduced myocardial blood flow</span><span class="headingEndMark"> — </span>In patients with idiopathic cardiomyopathy, reduced myocardial blood flow, as assessed by positron emission tomography at rest and after intravenous <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>, is an independent predictor of subsequent cardiac events (death or the development or progression of HF) [<a href="#rid66">66</a>]. This association is independent of other clinical and functional variables. Because of the decreased availability and higher cost of this test, it is unclear what its clinical role may be.</p><p class="headingAnchor" id="H21"><span class="h2">Atrial fibrillation</span><span class="headingEndMark"> — </span>The prevalence of AF in patients with HF varies from 10 to 30 percent, depending upon the population studied. There are conflicting data as to whether AF is an independent predictor of increased mortality in patients with HF; data from the SOLVD trials and the Framingham Heart Study suggest such an increase, while data from the V-HeFT I and II trials do not. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Several studies have demonstrated that there is an association between anemia and increased mortality in patients with HF, although it is unclear whether anemia is responsible for worse outcomes or merely a marker for more severe HF. At least one small study has suggested that erythropoietin therapy may reduce mortality in anemic HF patients [<a href="#rid67">67</a>]. However, benefit has not been proven and there is the potential for harm. (See  <a class="medical medical_review" href="/z/d/html/3483.html" rel="external">"Evaluation and management of anemia and iron deficiency in adults with heart failure", section on 'ESAs (not recommended)'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Diabetes</span><span class="headingEndMark"> — </span>The CHARM trials evaluated the role of an angiotensin II receptor blocker in the treatment HF due to both systolic and diastolic dysfunction. A retrospective analysis of 7599 patients from these trials assessed the prognostic significance of approximately 50 baseline variables [<a href="#rid3">3</a>]. In addition to age and LVEF, diabetes was among the most powerful independent predictors of mortality and HF hospitalizations.</p><p class="headingAnchor" id="H24"><span class="h1">PREDICTIVE MODELS</span><span class="headingEndMark"> — </span>There are drawbacks to using any single factor to determine prognosis or to guide therapy. Although the factors listed above influence survival, the aggregate effect of such factors on overall prognosis is difficult to quantify. Accordingly, a number of predictive models have been developed from retrospective data to more accurately quantify prognosis [<a href="#rid68">68-71</a>].</p><p>In general, prognostic risk models can be used in selected clinical scenarios to more accurately communicate prognosis to the patient but should not be routinely used to guide therapy [<a href="#rid72">72</a>].</p><p>Potential benefits of using prognostic models for HF include the following [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Enables patients and their caregivers to have a more realistic expectation of the prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enables appropriate allocation of resources, including transplantation, mechanical circulatory assist devices, and implantable defibrillators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enables selection of therapies most likely to positively affect the quality and quantity of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promotes open, honest communication between clinicians, patients, and their caregivers to define the goals of therapy.</p><p></p><p>Potential limitations of using prognostic models for HF include the following [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The model was derived from a population of patients different from patients seen in clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient compliance, preference, or attitudes are not incorporated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New therapies become available, making the models obsolete.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncertainty in applying the model to an individual patient cannot be quantified and this uncertainty may be difficult for clinicians to effectively explain to patients and their caregivers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scores from the models may replace informed, compassionate, clinician-patient conversations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scores have a limited impact on outcomes.</p><p></p><p>The role of predictive models as a component of routine care is unclear; most studies of risk scores assessed their accuracy and not their clinical impact. One trial found that providing clinicians with a measure of HF prognosis did not alter processes of care or outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>In a trial that included 3124 patients with HF who were randomly assigned to routine display of a one-year mortality estimate to their clinician via the electronic health record or to usual care, the combined risk of one-year mortality and 30-day hospital readmission was similar between the two groups (39 percent) [<a href="#rid73">73</a>]. In addition, clinician behavior, as measured by the use of either guideline-directed medical therapy or advanced HF therapies (eg, palliative care, cardiac transplantation) was similar between the groups.</p><p></p><p class="headingAnchor" id="H2919968097"><span class="h2">EFFECT model</span><span class="headingEndMark"> — </span>The EFFECT model was derived, tested, and intended to be used in patients hospitalized for HF [<a href="#rid68">68</a>]. The derivation cohort included 2624 patients in the EFFECT study, who presented with HF at 34 hospitals in Ontario, Canada between 1999 and 2001. The model was then validated in 1407 patients presenting between 1997 and 1999.</p><p>Multiple clinical characteristics, including both HF-related factors (respiratory rate, systolic pressure, blood urea nitrogen, and serum sodium concentration) and comorbidities (eg, chronic obstructive pulmonary disease [COPD], anemia, malignancy) were correlated with 30-day and one-year mortality. Points were assigned to each significant predictor; the sum of the points results in a risk score ranging from ≤60 (very low; 30-day mortality &lt;1 percent and one year mortality &lt;10 percent) to &gt;150 (very high; 30-day mortality &gt;50 percent and one year mortality &gt;70 percent).</p><p class="headingAnchor" id="H513037593"><span class="h2">Heart Failure Survival Score</span><span class="headingEndMark"> — </span>The Heart Failure Survival Score (HFSS) is another prospectively validated model, developed in and for patients with advanced HF (New York Heart Association [NYHA] class III or IV)  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>) [<a href="#rid69">69</a>]. This score was derived from a multivariable analysis of 268 ambulatory patients referred for consideration of cardiac transplantation and validated in 199 similar patients. The predictors of survival in the HFSS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of coronary artery disease</p><p class="bulletIndent1"><span class="glyph">●</span>Resting heart rate</p><p class="bulletIndent1"><span class="glyph">●</span>LVEF</p><p class="bulletIndent1"><span class="glyph">●</span>Mean arterial blood pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of an intraventricular conduction delay on ECG</p><p class="bulletIndent1"><span class="glyph">●</span>Serum sodium</p><p class="bulletIndent1"><span class="glyph">●</span>Peak VO<sub>2</sub></p><p></p><p>In a version of the HFSS that incorporates invasive hemodynamic data, pulmonary capillary wedge pressure is included as an eighth variable. The HFSS stratifies patients into low-, medium-, and high-risk categories, based upon a sum of the variables above multiplied by defined coefficients. Among the patients in the validation sample, one-year survival rates without transplant for these three strata were 88, 60, and 35 percent, respectively.</p><p>The HFSS is often used as an aid to selecting patients for cardiac transplantation. However, the above survival rates may not be applicable to current practice since the model was derived before the use of modern therapies that improve survival in patients with HF, including beta blockers, angiotensin II receptor blockers, aldosterone antagonists, implantable cardioverter-defibrillators, and cardiac resynchronization therapy [<a href="#rid74">74</a>]. In addition, some of these therapies directly affect some of the parameters in the risk model (eg, beta blockers and resting heart rate, and cardiac resynchronization therapy and conduction delay). (See  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications", section on 'Heart Failure Survival Score'</a>.)</p><p class="headingAnchor" id="H1577478982"><span class="h2">Seattle Heart Failure Model</span><span class="headingEndMark"> — </span>The Seattle Heart Failure Model differs from the prior models in two ways [<a href="#rid70">70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The model was derived and validated in a broad HF population, including both general outpatients and advanced HF patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The model incorporates a wide range of readily available clinical variables, including medications and devices.</p><p></p><p>The model was derived in 1125 advanced HF patients from the PRAISE trial (average LVEF 21 percent, average NYHA class 3.6). None of the patients in the derivation cohorts were treated with beta blockers, aldosterone antagonists, or implantable cardioverter-defibrillators (ICDs), but validation of the model in cohorts from subsequent trials evaluated the impact of these interventions. The model was prospectively validated in five additional cohorts totaling 9942 HF patients and 17,307 person-years of follow-up.</p><p>The diversity of the validation cohorts is illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Average LVEF ranged from 22 to 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Average NYHA class ranged from 2.2 to 2.9  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Wide ranges of use of beta blockers (24 to 72 percent) and potassium-sparing diuretics (5 to 35 percent)</p><p></p><p>Across these populations, the model provided an extremely accurate estimate of one-, two-, and three-year survival (R values ranging from 0.97 to 0.99).</p><p>The Seattle model also provides information about the likely mode of death. In an analysis of 10,538 ambulatory patients with predominantly HFrEF (NYHA class II to IV), the score was predictive of the risk of sudden death and of pump failure [<a href="#rid75">75</a>]. Compared with patients with a score of 0, the risk of sudden death progressively increased with higher scores, up to a sevenfold higher risk with a score of 4. Conversely, the proportion of deaths caused by sudden death versus pump failure decreased from a ratio of 7:1 with a score of 0 to a ratio of 1:2 with a score of 4.</p><p>An online calculator is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdepts.washington.edu%2Fshfm%2F%3Fwidth%3D1024%26height%3D819&amp;token=3LnavMR4lJzMwcjXSJ9A9sPc6vbj2UCuaY0DDLsFjBDHbKLiIPIjTYpy%2BttyJB%2FCEOF9%2BKB6wld1x8JdDY76xq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=3477" target="_blank">https://depts.washington.edu/shfm/?width=1024&amp;height=819</a>. The calculator can also estimate the effect of adding new therapies on the risk of mortality.</p><p class="headingAnchor" id="H25"><span class="h1">OTHER PREDICTORS OF SURVIVAL</span><span class="headingEndMark"> — </span>There are a number of other findings that have been associated with the outcome of patients with HF.</p><p class="headingAnchor" id="H26"><span class="h2">Physical findings</span></p><p class="headingAnchor" id="H27"><span class="h3">S3 gallop and jugular venous pressure</span><span class="headingEndMark"> — </span>The presence of an S3 gallop and/or elevated jugular venous pressure appear to have prognostic significance. In a review of 2569 patients from the SOLVD treatment trial, 24 percent had an S3 gallop and 11.8 percent had an elevated jugular venous pressure [<a href="#rid76">76</a>]. After adjusting for other markers of disease severity, an S3 gallop and elevated jugular venous pressure were each associated with an increased risk of hospitalization for HF (relative risk 1.42 and 1.32, respectively) and of death from pump failure (relative risk 1.40 and 1.37). One limitation to these observations is the operator-dependence for the detection of these physical findings.</p><p class="headingAnchor" id="H28"><span class="h3">Functional MR</span><span class="headingEndMark"> — </span>Patients with advanced HF often develop functional or secondary mitral regurgitation (MR) due to annular enlargement secondary to LV dilatation and/or papillary displacement due to LV remodeling. Although data are limited, patients with moderate to severe MR appear to have a worse prognosis.</p><p class="headingAnchor" id="H29"><span class="h2">C-reactive protein</span><span class="headingEndMark"> — </span>Elevations in serum C-reactive protein (CRP) are associated with worse outcomes in patients with atherosclerotic cardiovascular disease. Data in HF have been limited, but suggest an association between CRP and outcomes [<a href="#rid77">77-79</a>]. (See  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p>The possible predictive value of serum CRP was addressed in a post hoc analysis from the Val-HeFT trial of <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">valsartan</a> therapy in HF [<a href="#rid77">77</a>]. The median serum CRP was higher in patients with HF compared with the general population and the cumulative likelihood of death or a first morbid event increased progressively with quartiles of serum CRP (eg, the adjusted hazard ratio [HR] for mortality was 1.53 in the highest compared with the lowest quartile for serum CRP). At one year, serum CRP was stable in the placebo group but fell in patients receiving valsartan who were not receiving an ACE inhibitor but not in those who were.</p><p>Similar findings were noted in a review of 546 consecutive patients (mean age 56) with stable systolic HF (mean LVEF 33 percent) [<a href="#rid78">78</a>]. Almost all patients were treated with ACE inhibitors and beta blockers. A serum CRP &gt;3 mg/L was an independent predictor of cardiovascular mortality (HR 1.78). This effect, which was only seen in patients with ischemic cardiomyopathy, was independent of other major predictors, such as peak VO<sub>2</sub> and serum B-type natriuretic peptide (BNP).</p><p class="headingAnchor" id="H30"><span class="h2">Heart rate variability</span><span class="headingEndMark"> — </span>Reduced heart rate variability, which indicates increased sympathetic or reduced parasympathetic tone [<a href="#rid80">80-82</a>], is associated with a worse prognosis in patients with HF. In one study of 433 patients, the annual mortality for those with standard deviation of normal RR intervals (SDNN) of &gt;100 ms, 50 to 100 ms, and &lt;50 ms was 5.5, 12.7, and 51.4 percent, respectively; values below 100 ms indicate absence of heart rate variability  (<a class="graphic graphic_figure graphicRef62928" href="/z/d/graphic/62928.html" rel="external">figure 15</a>) [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/993.html" rel="external">"Evaluation of heart rate variability"</a>.)</p><p class="headingAnchor" id="H31"><span class="h2">Planar QRS-T angle</span><span class="headingEndMark"> — </span>In a report of 455 patients with nonischemic cardiomyopathy, New York Heart Association (NYHA) class I to III HF, and nonsustained ventricular tachycardia (VT) or frequent ventricular ectopy, a planar QRS-T angle greater than 90 degrees was a predictor of the composite end point of total mortality, appropriate implantable cardioverter-defibrillator shock, or resuscitated cardiac arrest [<a href="#rid83">83</a>]. Changes in the QRS-T angle correlated with changes in LVEF and QRS duration over time.</p><p class="headingAnchor" id="H32"><span class="h2">Troponins</span><span class="headingEndMark"> — </span>Circulating troponin levels are a sensitive marker of acute myocardial injury but elevations also occur in a variety of other disorders. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a> and  <a class="medical medical_review" href="/z/d/html/1469.html" rel="external">"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome"</a>.)</p><p>Elevations in circulating troponin T (TnT) and troponin I (TnI) are predictors of adverse outcomes in hospitalized as well as stable ambulatory patients with HF [<a href="#rid53">53,84-93</a>]. Elevations in both troponin and BNP are associated with an increased risk compared with elevations in either measurement alone [<a href="#rid53">53,89,92,93</a>].</p><p>The predictive value of plasma troponin T is illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 4053 patients with chronic HF with LVEF &lt;40 percent enrolled in the Val-HeFT trial, plasma troponin T was detectable in 10.4 percent of the population with the traditional (cTnT) assay and in 92 percent of the population using a highly sensitive assay (hsTnT) [<a href="#rid89">89</a>]. In models adjusting for other risk factors, both baseline TnT and baseline hsTnT were significantly associated with all-cause mortality and first hospitalization for HF at median two-year follow-up. In addition, hsTnT was significantly associated with mortality in the 90 percent of the population with undetectable cTnT by the traditional assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baseline cTnI level was an independent predictor of risk of first hospitalization for HF after exclusion of myocardial infarction (per 0.01 microg/L of cTnI; adjusted HR 1.31, 95% CI 1.16-1.47) during nine-year median follow-up of a population of 1089 70-year-old men [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baseline hsTnT level and increases in hsTnT levels were significantly associated with new onset HF and cardiovascular death during 11.8-year median follow-up in a nationwide cohort of 4221 adults ≥65 years of age enrolled in the Cardiovascular Health Study [<a href="#rid91">91</a>]. The addition of baseline hsTNT to clinical risk factors yielded a significant but modest improvement in discrimination of risk.</p><p></p><p>Small studies have found an association between worsening LVEF and baseline troponin level [<a href="#rid88">88</a>] or persistently elevated troponin levels [<a href="#rid85">85</a>]. Persistently elevated troponin levels were also associated with higher cardiac event rates [<a href="#rid85">85,90</a>].</p><p>Myocardial strain and myocyte death are two related mechanisms that can contribute to the troponin elevations. (See  <a class="medical medical_review" href="/z/d/html/1469.html" rel="external">"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome", section on 'Heart failure'</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Low serum cholesterol</span><span class="headingEndMark"> — </span>In contrast to the beneficial effect of a low serum cholesterol induced by statin therapy in patients with coronary heart disease, a low serum cholesterol in patients with HF is associated with higher mortality. This issue and the possible role of statin therapy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1493.html" rel="external">"Statin therapy in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H34"><span class="h2">Hyperuricemia</span><span class="headingEndMark"> — </span>An elevated serum uric acid (UA) concentration was associated with an increase in mortality in an evaluation of 112 patients with HF [<a href="#rid94">94</a>]. These patients formed a derivation sample to identify a threshold value for UA of 9.5 mg/dL (565 micromol/L). In a validation sample of 182 patients with HF, those with a serum UA above the threshold value had a much poorer survival rate at four years than those with lower levels (19 versus 79 percent).</p><p>These observations do not address the issue of whether hyperuricemia is simply a marker for more severe heart disease, since both a low cardiac output and diuretic therapy reduce uric acid excretion. There is some evidence that lowering uric acid may be beneficial in patients with HF. In patients with hyperuricemia and HF, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> therapy improved endothelial function and local blood flow [<a href="#rid95">95</a>].</p><p>A similar effect on endothelial function has been seen in patients with HF without hyperuricemia in association with reduced markers of oxidative stress, suggesting that xanthine oxidase inhibition itself may be important [<a href="#rid96">96</a>]. Furthermore, in an animal model of HF, long-term <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> therapy improved LV function and prevented LV remodeling, benefits that were associated with a transient reduction in reactive oxygen species [<a href="#rid97">97</a>]. The EXACT-HF Trial tested the effect of allopurinol therapy in 253 patients with symptomatic HF and an elevated serum uric acid (&gt;9.5 mg/dL). In this trial, allopurinol treatment for 24 weeks deceased serum uric acid but had no effect on several markers of clinical outcome including survival, worsening HF, patient global assessment, quality of life, submaximal exercise capacity, and LVEF. These results suggest that although elevated uric acid is a marker of adverse outcomes, the lowering of uric acid with allopurinol is not clinically effective.</p><p>Hyperuricemia has also been evaluated as a risk factor for coronary heart disease. (See  <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">"Overview of possible risk factors for cardiovascular disease", section on 'Urate'</a>.)</p><p class="headingAnchor" id="H35"><span class="h2">Weight loss and body mass index</span><span class="headingEndMark"> — </span>Weight loss in patients with HF (sometimes called "cardiac cachexia" if severe) is linked to a poor prognosis. Both increased energy expenditure and decreased energy intake may contribute [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/z/d/html/2770.html" rel="external">"Approach to the patient with unintentional weight loss"</a>.)</p><p>In an analysis of data on 1929 patients from the SOLVD treatment trial, 39 percent of whom had died by three years, weight loss of 6 percent at eight months was the best threshold value for predicting reduced survival [<a href="#rid99">99</a>]. This model was then validated using data on 619 patients from the V-HeFT II trial, 30 percent of whom had died at nine months. Weight loss of 6 percent or more at any time during follow-up was a predictor of mortality (adjusted HR 2.10, 95% CI 1.77-2.49).</p><p>In an analysis of data on 7599 patients with symptomatic HF with a broad range of LVEF from the CHARM clinical trials, 29 percent died by 38 months [<a href="#rid100">100</a>]. Patients with body mass index (BMI) &lt;30 kg/m<sup>2</sup> had greater mortality than those with BMI between 30 and 34.9 kg/m<sup>2</sup>; this association was not altered by LVEF. Lower BMI was associated with a greater risk of all-cause death in patients without edema but not in those with edema.</p><p>High plasma adiponectin levels are an independent predictor of mortality in chronic HF patients with systolic dysfunction [<a href="#rid101">101,102</a>]. Plasma adiponectin levels are negatively associated with BMI, so the elevated adiponectin levels in HF patients may be a marker for wasting.</p><p>Although obesity is a risk factor for cardiovascular disease, including HF and mortality, it does not appear to be a risk factor for mortality in HF, despite its association with hypertension, diabetes, and hypercholesterolemia [<a href="#rid103">103,104</a>]. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H36"><span class="h2">Hypoalbuminemia and liver function abnormalities</span><span class="headingEndMark"> — </span>Hypoalbuminemia is common among patients with HF though its causes have not been established [<a href="#rid105">105,106</a>]. In a study of 1726 systolic HF patients (LVEF 23±7 percent), hypoalbuminemia was present in 25 percent and it was a risk factor for one- and five-year mortality (HR 2.2 for both), even after adjustment for multiple prognostic factors including BMI, LVEF, and creatinine [<a href="#rid105">105</a>]. Hypoalbuminemia was not associated with BMI. Factors in addition to nutritional status, such as hepatic function, hemodilution, and inflammatory state, may contribute to hypoalbuminemia.</p><p>The predictive value of liver function tests and albumin level was evaluated in 2679 patients including 1594 with impaired LV systolic function (LVEF ≤40 percent) and 1085 with preserved LV function (LVEF &gt;40 percent) enrolled in the CHARM program [<a href="#rid106">106</a>]. Hypoalbuminemia was present in 18 percent, elevated alkaline phosphatase in 14 percent, elevated total bilirubin in 13 percent, elevated alanine aminotransferase in 3 percent, and elevated aspartate aminotransferase in 4 percent. Elevated total bilirubin was nearly twice as common among patients with impaired LVEF as compared with those with preserved LVEF (16 versus 9 percent); the prevalences of the other abnormalities were not markedly different between the two LVEF groups. In univariate analysis adjusted for clinical variables, hypoalbuminemia as well as elevated total bilirubin were predictors of outcomes (cardiovascular death or HF hospitalization) with median 38 months follow-up. In a multivariable model including all clinical and laboratory predictors, total bilirubin (but not albumin) remained a significant predictor of outcomes (HR 1.1 per 1SD).</p><p class="headingAnchor" id="H37"><span class="h2">Hematologic abnormalities</span><span class="headingEndMark"> — </span>As noted above, anemia is associated with increased mortality in patients with HF. (See <a class="local">'Anemia'</a> above.)</p><p>Polycythemia, as well as anemia, is associated with increased mortality in patients with HF. This was illustrated in a study of 3044 patients participating in the ELITE II trial [<a href="#rid107">107</a>]. The relationship between baseline hemoglobin concentration and survival was U-shaped, with the highest two-year survival rate (83 percent) among those with a hemoglobin of 14 to 15 g/dL. Patients in the subsets with lowest and highest hemoglobin (&lt;12.5 g/dL and &gt;15 g/dL, respectively) both had lower two-year survival rates (75 and 78 percent, respectively). The reason for the association between a high hemoglobin concentration and mortality noted in this study is not clear. While the correlation persisted after correction for the diagnosis of chronic obstructive pulmonary disorder (in 9 percent of the subjects), no data were provided on the incidence of cigarette smoking or its correlation with hemoglobin concentration.</p><p>Another independent predictor of morbidity and mortality is an elevated red cell distribution width (RDW) [<a href="#rid108">108</a>]. Among 36 laboratory values considered in the CHARM program of chronic HF patients (with depressed and preserved LVEF), higher RDW showed the greatest association with morbidity and mortality. This finding was replicated in the Duke Databank, in which higher RDW was strongly associated with all-cause mortality. (See  <a class="medical medical_review" href="/z/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia", section on 'RDW (size variability)'</a>.)</p><p>Other hematologic abnormalities have been associated with increased mortality, such as a decreased percentage of lymphocytes, which reflect stress-induced cortisol release [<a href="#rid109">109</a>]; a white blood cell count &gt;7000/microL in ischemic cardiomyopathy [<a href="#rid110">110</a>]; and an erythrocyte sedimentation rate ≥15 mm/h, which reflects an acute phase response to inflammation or infection [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">"Acute phase reactants"</a>.)</p><p class="headingAnchor" id="H38"><span class="h2">Low plasma T3</span><span class="headingEndMark"> — </span>The role of plasma T3 (triiodothyronine) concentrations as a prognostic indicator was evaluated in a report of 281 patients with systolic HF, 122 of whom (43 percent) had a plasma total T3 concentration below the lower limit of normal (≤80 ng/dL [1.2 nmol/L]) [<a href="#rid112">112</a>]. Low plasma T3 was an independent predictor of mortality independent of the LVEF. Whether low plasma T3 is a prognostic marker or contributes to progressive disease is not known.</p><p class="headingAnchor" id="H39"><span class="h2">Cytokines and other markers of inflammation</span><span class="headingEndMark"> — </span>A number of cytokines and other markers of inflammation may be important in the pathogenesis of HF and serum levels may provide prognostic information. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">"Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Other factors'</a>.)</p><p class="headingAnchor" id="H40"><span class="h2">Anabolic hormones</span><span class="headingEndMark"> — </span>An imbalance in anabolic and catabolic forces, favoring catabolism, is present in patients with advanced HF. Deficiencies in anabolic hormones (eg, testosterone, dehydroepiandrosterone, and insulin-like growth factor) are associated with increased morbidity and mortality in the general population of adult men, and may have similar implications in men with HF.</p><p>This possibility was supported in a study of 208 men with HF, in whom anabolic hormone deficiencies were common [<a href="#rid113">113</a>]. At a follow-up of three years, these deficiencies were associated with increased mortality, and mortality rates were further increased among men with multiple hormone deficiencies. It is not known if these deficiencies contributed to the severity of HF, were themselves the result of advanced HF, or if they were simply markers of the severity of general chronic illness. In addition, because anabolic deficiencies are known to be associated with worse outcomes in the general population, it is not known if this finding is uniquely ominous in men with HF.</p><p class="headingAnchor" id="H41"><span class="h2">Albuminuria</span><span class="headingEndMark"> — </span>Albuminuria may be an adverse prognostic indicator in patients with HF as well as in those with other cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/1545.html" rel="external">"Moderately increased albuminuria (microalbuminuria) and cardiovascular disease"</a>.)</p><p>Albuminuria (identified by spot urinary albumin to creatinine ratio) was common in the class II to IV HF patients enrolled in the CHARM trials; 30 percent had microalbuminuria and 11 percent had macroalbuminuria. Albuminuria was associated with increased risk of mortality as well as the composite outcome (death from cardiovascular causes or admission to hospital with worsening HF), even after adjustment for other prognostic variables, including renal function and diabetes [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H42"><span class="h2">Depression</span><span class="headingEndMark"> — </span>Depression appears to be both relatively common and associated with a worse prognosis in patients with HF [<a href="#rid115">115</a>]. In one study, major depression was associated with increased mortality at three and six months (odds ratio 2.5 and 2.23, respectively, compared with no depression) and with an increased rate of readmission (odds ratio 1.9 and 3.07, respectively) [<a href="#rid116">116</a>]. In another report, higher Beck Depression Inventory scores were independently associated with greater increases in mortality starting at approximately three months and continuing throughout the mean follow-up period of 971 days [<a href="#rid117">117</a>]. In this cohort, depression, but not antidepressant or selective serotonin reuptake inhibitor (SSRI) use, was independently associated with increased mortality [<a href="#rid118">118</a>].</p><p>Other psychosocial factors, such as marital quality, also are of prognostic importance [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/z/d/html/4851.html" rel="external">"Psychosocial factors in sudden cardiac arrest"</a>.)</p><p>Randomized trials evaluating the effect of psychological interventions on the outcome of depressed patients with HF have not been performed [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H43"><span class="h2">mIBG imaging</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9084" href="/z/d/drug information/9084.html" rel="external">Iobenguane I-123 (diagnostic)</a> (also known as iodone-123 metaiodobenzylguanidine [mIBG]) is an analog of norepinephrine (NE) that is taken up into cardiac sympathetic nerve endings in the same manner as NE. This uptake is decreased in HF. Radionuclide scintigraphy using I-123-mIBG correlates with established indices of HF severity, including LVEF, CI, PCWP and peak VO<sub>2</sub> [<a href="#rid121">121</a>]. Findings on mIBG imaging are associated with risk of death or transplantation [<a href="#rid121">121</a>], risk of sudden death [<a href="#rid122">122</a>] and with the likelihood of benefit from beta blocker therapy [<a href="#rid123">123</a>]. The mIBG imaging parameter with greatest prognostic value has differed among studies [<a href="#rid121">121,123,124</a>].</p><p>The prospective multicenter ADMIRE-HF study evaluated the predictive value of mIBG imaging in 961 subjects with NYHA functional class II or III HF  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>) and LVEF ≤35 percent [<a href="#rid125">125</a>]. The heart/mediastinal uptake ratio (H/M) on mIBG imaging was compared with time to first occurrence of NYHA functional class progression, potentially life-threatening arrhythmic event (sustained ventricular tachycardia, cardiac arrest, or appropriate ICD discharge), or cardiac death. Twenty-five percent of subjects experienced events during median follow-up of 17 months. The two-year event rate was 15 percent for an H/M ≥1.6 as compared with 37 percent for an H/M ≤1.6. The H/M was a predictor for each of the individual event categories of HF progression, arrhythmic events and cardiac death (HR 0.48, 0.37, and 0.14, respectively). In a multivariable model, H/M, LVEF, BNP, and NYHA functional class were independent predictors for time to cardiac events.</p><p>Subsequent to the ADMIRE-HF study, the prognostic value of mIBG imaging in HF patients with longer-term follow-up (mean 78 months) was reported from a pooled analysis of six prospective HF cohort studies [<a href="#rid126">126</a>]. All-cause mortality was inversely related to H/M ratio, with annual all-cause mortality exceeding 7 percent for those with H/M ratio ≤1.2 (compared with less than 2 percent for patients with H/M ratio ≥2).</p><p class="headingAnchor" id="H44"><span class="h2">Sleep disordered breathing</span><span class="headingEndMark"> — </span>Cheyne-Stokes respiration and sleep apnea are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7682.html" rel="external">"Sleep-disordered breathing in heart failure", section on 'Prognostic implications'</a>.)</p><p class="headingAnchor" id="H3734797210"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H10432610"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3446.html" rel="external">"Patient education: Heart failure (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H45"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of prognosis in patients with heart failure</strong> – Among patients with heart failure (HF) who are considering therapies such as heart transplantation, left ventricular (LV) assist device placement, or palliative care, prognostic information can further inform a discussion of the risks and benefits of therapy. However, for most diagnostic and treatment decisions, the role of prognosis is limited. (See  <a class="medical medical_review" href="/z/d/html/3495.html" rel="external">"Management of refractory heart failure with reduced ejection fraction", section on 'Components of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications", section on 'Prognosis scores'</a> and  <a class="medical medical_review" href="/z/d/html/3511.html" rel="external">"Palliative care for patients with advanced heart failure: Indications and systems of care", section on 'Disease course and prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors</strong> – Patients with HF often have one or more factors associated with decreased survival despite maximal medical therapy. Routine evaluation to estimate severity should include determination of New York Heart Association (NYHA) class; echocardiography to measure LV ejection fraction (LVEF), assessment of diastolic and right ventricular function, and identification of other abnormalities such as regional wall motion abnormalities; and measurement of the plasma natriuretic peptides, sodium, and creatinine concentrations. (See <a class="local">'Major predictors of survival'</a> above and  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic models</strong> – In general, prognostic risk models can be used in selected clinical scenarios to more accurately communicate prognosis to the patient but should not be routinely used to guide therapy. (See <a class="local">'Predictive models'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000; 140:840.</a></li><li><a class="nounderline abstract_t">Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77:1017.</a></li><li><a class="nounderline abstract_t">Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27:65.</a></li><li><a class="nounderline abstract_t">Alla F, Briançon S, Juillière Y, et al. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J 2000; 139:895.</a></li><li><a class="nounderline abstract_t">Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30:1002.</a></li><li><a class="nounderline abstract_t">Cohn JN, Archibald DG, Francis GS, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987; 75:IV49.</a></li><li><a class="nounderline abstract_t">Wilson JR, Schwartz JS, Sutton MS, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983; 2:403.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.</a></li><li><a class="nounderline abstract_t">CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429.</a></li><li><a class="nounderline abstract_t">Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004; 43:2022.</a></li><li><a class="nounderline abstract_t">Quiñones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000; 35:1237.</a></li><li><a class="nounderline abstract_t">Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994; 90:2645.</a></li><li><a class="nounderline abstract_t">Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112:3738.</a></li><li><a class="nounderline abstract_t">Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65:903.</a></li><li><a class="nounderline abstract_t">Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989; 14:564.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.</a></li><li><a class="nounderline abstract_t">Pozzoli M, Traversi E, Cioffi G, et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 1997; 95:1222.</a></li><li><a class="nounderline abstract_t">Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22:808.</a></li><li><a class="nounderline abstract_t">Xie GY, Berk MR, Smith MD, et al. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 1994; 24:132.</a></li><li><a class="nounderline abstract_t">Temporelli PL, Corrà U, Imparato A, et al. Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. J Am Coll Cardiol 1998; 31:1591.</a></li><li><a class="nounderline abstract_t">Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.</a></li><li><a class="nounderline abstract_t">Duncan AM, Lim E, Gibson DG, Henein MY. Effect of dobutamine stress on left ventricular filling in ischemic dilated cardiomyopathy: pathophysiology and prognostic implications. J Am Coll Cardiol 2005; 46:488.</a></li><li><a class="nounderline abstract_t">Hansen A, Haass M, Zugck C, et al. Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failure. J Am Coll Cardiol 2001; 37:1049.</a></li><li><a class="nounderline abstract_t">Marcassa C, Galli M, Baroffio C, et al. Independent and incremental prognostic value of (201)Tl lung uptake at rest in patients with severe postischemic left ventricular dysfunction. Circulation 2000; 102:1795.</a></li><li><a class="nounderline abstract_t">Juillière Y, Barbier G, Feldmann L, et al. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997; 18:276.</a></li><li><a class="nounderline abstract_t">Sun JP, James KB, Yang XS, et al. Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities. Am J Cardiol 1997; 80:1583.</a></li><li><a class="nounderline abstract_t">Karatasakis GT, Karagounis LA, Kalyvas PA, et al. Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol 1998; 82:329.</a></li><li><a class="nounderline abstract_t">de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32:948.</a></li><li><a class="nounderline abstract_t">Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183.</a></li><li><a class="nounderline abstract_t">Hung J, Koelling T, Semigran MJ, et al. Usefulness of echocardiographic determined tricuspid regurgitation in predicting event-free survival in severe heart failure secondary to idiopathic-dilated cardiomyopathy or to ischemic cardiomyopathy. Am J Cardiol 1998; 82:1301.</a></li><li><a class="nounderline abstract_t">Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105:1663.</a></li><li><a class="nounderline abstract_t">Grayburn PA, Appleton CP, DeMaria AN, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2005; 45:1064.</a></li><li><a class="nounderline abstract_t">Bruch C, Gotzmann M, Stypmann J, et al. Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure: incremental prognostic value of QRS duration and a restrictive mitral filling pattern. J Am Coll Cardiol 2005; 45:1072.</a></li><li><a class="nounderline abstract_t">Rossi A, Cicoira M, Zanolla L, et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40:1425.</a></li><li><a class="nounderline abstract_t">Rossi A, Cicoira M, Bonapace S, et al. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart 2007; 93:1420.</a></li><li><a class="nounderline abstract_t">Ramahi TM, Longo MD, Cadariu AR, et al. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy. Eur Heart J 2001; 22:849.</a></li><li><a class="nounderline abstract_t">Pratali L, Picano E, Otasevic P, et al. Prognostic significance of the dobutamine echocardiography test in idiopathic dilated cardiomyopathy. Am J Cardiol 2001; 88:1374.</a></li><li><a class="nounderline abstract_t">Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299:2656.</a></li><li><a class="nounderline abstract_t">Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398.</a></li><li><a class="nounderline abstract_t">Tabrizi F, Englund A, Rosenqvist M, et al. Influence of left bundle branch block on long-term mortality in a population with heart failure. Eur Heart J 2007; 28:2449.</a></li><li><a class="nounderline abstract_t">Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.</a></li><li><a class="nounderline abstract_t">Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.</a></li><li><a class="nounderline abstract_t">Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278.</a></li><li><a class="nounderline abstract_t">Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509.</a></li><li><a class="nounderline abstract_t">Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587.</a></li><li><a class="nounderline abstract_t">Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23:1410.</a></li><li><a class="nounderline abstract_t">Hülsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:1695.</a></li><li><a class="nounderline abstract_t">de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43:1584.</a></li><li><a class="nounderline abstract_t">Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47:85.</a></li><li><a class="nounderline abstract_t">Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49:1943.</a></li><li><a class="nounderline abstract_t">Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625.</a></li><li><a class="nounderline abstract_t">Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007; 116:249.</a></li><li><a class="nounderline abstract_t">Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392.</a></li><li><a class="nounderline abstract_t">Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. J Am Coll Cardiol 1997; 29:1199.</a></li><li><a class="nounderline abstract_t">Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103:1428.</a></li><li><a class="nounderline abstract_t">Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372:817.</a></li><li><a class="nounderline abstract_t">Domanski MJ, Mitchell GF, Norman JE, et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33:951.</a></li><li><a class="nounderline abstract_t">Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681.</a></li><li><a class="nounderline abstract_t">Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38:955.</a></li><li><a class="nounderline abstract_t">Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102:203.</a></li><li><a class="nounderline abstract_t">Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 1997; 80:519.</a></li><li><a class="nounderline abstract_t">Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66:1348.</a></li><li><a class="nounderline abstract_t">Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006; 151:76.</a></li><li><a class="nounderline abstract_t">Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987.</a></li><li><a class="nounderline abstract_t">Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002; 105:186.</a></li><li><a class="nounderline abstract_t">Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775.</a></li><li><a class="nounderline abstract_t">Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581.</a></li><li><a class="nounderline abstract_t">Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95:2660.</a></li><li><a class="nounderline abstract_t">Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424.</a></li><li><a class="nounderline abstract_t">Brophy JM, Dagenais GR, McSherry F, et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004; 116:300.</a></li><li><a class="nounderline abstract_t">Goldberg LR, Jessup M. A time to be born and a time to die. Circulation 2007; 116:360.</a></li><li><a class="nounderline abstract_t">Ahmad T, Desai NR, Yamamoto Y, et al. Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure: The REVEAL-HF Randomized Clinical Trial. JAMA Cardiol 2022; 7:905.</a></li><li><a class="nounderline abstract_t">Gardner RS, McDonagh TA, MacDonald M, et al. Who needs a heart transplant? Eur Heart J 2006; 27:770.</a></li><li><a class="nounderline abstract_t">Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007; 116:392.</a></li><li><a class="nounderline abstract_t">Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345:574.</a></li><li><a class="nounderline abstract_t">Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112:1428.</a></li><li><a class="nounderline abstract_t">Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26:2245.</a></li><li><a class="nounderline abstract_t">Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006; 151:845.</a></li><li><a class="nounderline abstract_t">Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98:1510.</a></li><li><a class="nounderline abstract_t">Ho KK, Moody GB, Peng CK, et al. Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. Circulation 1997; 96:842.</a></li><li><a class="nounderline abstract_t">Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79:1645.</a></li><li><a class="nounderline abstract_t">Pavri BB, Hillis MB, Subacius H, et al. Prognostic value and temporal behavior of the planar QRS-T angle in patients with nonischemic cardiomyopathy. Circulation 2008; 117:3181.</a></li><li><a class="nounderline abstract_t">You JJ, Austin PC, Alter DA, et al. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J 2007; 153:462.</a></li><li><a class="nounderline abstract_t">Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103:369.</a></li><li><a class="nounderline abstract_t">Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004; 110:2376.</a></li><li><a class="nounderline abstract_t">Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96:2953.</a></li><li><a class="nounderline abstract_t">Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108:833.</a></li><li><a class="nounderline abstract_t">Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116:1242.</a></li><li><a class="nounderline abstract_t">Miller WL, Hartman KA, Burritt MF, et al. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009; 54:1715.</a></li><li><a class="nounderline abstract_t">deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010; 304:2494.</a></li><li><a class="nounderline abstract_t">Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13:718.</a></li><li><a class="nounderline abstract_t">Sundström J, Ingelsson E, Berglund L, et al. Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J 2009; 30:773.</a></li><li><a class="nounderline abstract_t">Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991.</a></li><li><a class="nounderline abstract_t">Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619.</a></li><li><a class="nounderline abstract_t">Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106:221.</a></li><li><a class="nounderline abstract_t">Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005; 26:1544.</a></li><li><a class="nounderline abstract_t">Aquilani R, Opasich C, Verri M, et al. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 2003; 42:1218.</a></li><li><a class="nounderline abstract_t">Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361:1077.</a></li><li><a class="nounderline abstract_t">Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 116:627.</a></li><li><a class="nounderline abstract_t">Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112:1756.</a></li><li><a class="nounderline abstract_t">Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28:1723.</a></li><li><a class="nounderline abstract_t">Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38:789.</a></li><li><a class="nounderline abstract_t">Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 2007; 153:74.</a></li><li><a class="nounderline abstract_t">Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155:883.</a></li><li><a class="nounderline abstract_t">Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11:170.</a></li><li><a class="nounderline abstract_t">Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25:1021.</a></li><li><a class="nounderline abstract_t">Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50:40.</a></li><li><a class="nounderline abstract_t">Ommen SR, Hodge DO, Rodeheffer RJ, et al. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation 1998; 97:19.</a></li><li><a class="nounderline abstract_t">Cooper HA, Exner DV, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1999; 84:252.</a></li><li><a class="nounderline abstract_t">Sharma R, Rauchhaus M, Ponikowski PP, et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000; 36:523.</a></li><li><a class="nounderline abstract_t">Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005; 118:132.</a></li><li><a class="nounderline abstract_t">Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114:1829.</a></li><li><a class="nounderline abstract_t">Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374:543.</a></li><li><a class="nounderline abstract_t">Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48:1527.</a></li><li><a class="nounderline abstract_t">Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161:1849.</a></li><li><a class="nounderline abstract_t">Jiang W, Kuchibhatla M, Clary GL, et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007; 154:102.</a></li><li><a class="nounderline abstract_t">O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008; 168:2232.</a></li><li><a class="nounderline abstract_t">Coyne JC, Rohrbaugh MJ, Shoham V, et al. Prognostic importance of marital quality for survival of congestive heart failure. Am J Cardiol 2001; 88:526.</a></li><li><a class="nounderline abstract_t">Lane DA, Chong AY, Lip GY. Psychological interventions for depression in heart failure. Cochrane Database Syst Rev 2005; :CD003329.</a></li><li><a class="nounderline abstract_t">Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999; 33:759.</a></li><li><a class="nounderline abstract_t">Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009; 53:426.</a></li><li><a class="nounderline abstract_t">Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141:645.</a></li><li><a class="nounderline abstract_t">Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003; 41:231.</a></li><li><a class="nounderline abstract_t">Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010; 55:2212.</a></li><li><a class="nounderline abstract_t">Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013; 6:772.</a></li></ol></div><div id="topicVersionRevision">Topic 3477 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099986" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644628" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219658" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predictors of mortality and morbidity in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783225" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316531" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552302" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6192158" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1463530" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2057034" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883575" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172407" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758966" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994804" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330684" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2138849" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2768707" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386652" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054853" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354816" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006256" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626839" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517230" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053963" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of dobutamine stress on left ventricular filling in ischemic dilated cardiomyopathy: pathophysiology and prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263607" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023934" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Independent and incremental prognostic value of (201)Tl lung uptake at rest in patients with severe postischemic left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043845" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9416940" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708662" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768716" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153735" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9832116" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Usefulness of echocardiographic determined tricuspid regurgitation in predicting event-free survival in severe heart failure secondary to idiopathic-dilated cardiomyopathy or to ischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940544" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15808765" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15808766" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure: incremental prognostic value of QRS duration and a restrictive mitral filling pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392832" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164482" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11350094" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11741555" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prognostic significance of the dobutamine echocardiography test in idiopathic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544725" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11868043" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17670760" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Influence of left bundle branch block on long-term mortality in a population with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3002660" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6382011" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628948" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244219" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079662" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909822" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822098" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120815" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386669" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : B-type natriuretic peptide levels in obese patients with advanced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498579" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774989" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592074" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021226" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137213" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11245648" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757091" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10091821" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716471" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583864" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10889132" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Renal function, neurohormonal activation, and survival in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285672" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Association between diuretic use, clinical response, and death in acute heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2244566" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368295" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The association between blood pressure and mortality in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697315" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Renal impairment and outcomes in heart failure: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790699" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401110" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625335" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193435" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534009" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The Seattle Heart Failure Model: prediction of survival in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984814" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646592" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A time to be born and a time to die.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35947362" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure: The REVEAL-HF Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449246" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Who needs a heart transplant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620506" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prediction of mode of death in heart failure: the Seattle Heart Failure Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529211" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129801" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : C-reactive protein in heart failure: prognostic value and the effect of valsartan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183690" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569545" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Inflammation and long-term mortality in acute congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9769304" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264491" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202356" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574059" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prognostic value and temporal behavior of the planar QRS-T angle in patients with nonischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383280" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Relation between cardiac troponin I and mortality in acute decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157687" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477403" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386162" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Circulating cardiac troponin I in severe congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12912820" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698733" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850213" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21078811" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21551163" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264749" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cardiac troponin-I and risk of heart failure: a community-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707250" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045167" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12105162" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Allopurinol improves endothelial dysfunction in chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872033" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522484" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Is nutritional intake adequate in chronic heart failure patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672310" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638930" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157772" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507366" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527635" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The relationship between obesity and mortality in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174642" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440336" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Albumin levels predict survival in patients with systolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168515" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191772" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601544" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443426" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Predictive power of the relative lymphocyte concentration in patients with advanced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496431" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD])</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10933367" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15694896" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Triiodothyronine levels for risk stratification of patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030678" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683640" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Albuminuria in chronic heart failure: prevalence and prognostic importance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045884" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493126" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17584561" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Relationship between depressive symptoms and long-term mortality in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001200" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Antidepressant use, depression, and survival in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524062" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prognostic importance of marital quality for survival of congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674906" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Psychological interventions for depression in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080478" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179201" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275933" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535815" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20188504" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845574" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
